- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 5, 2024
Discovery & Translation
Distillery spotlight: new Alzheimer’s mechanisms from academia
BioCentury’s survey of the 2023 translational literature highlights a cluster of neuron-targeting mechanisms for Alzheimer’s disease
BioCentury | May 5, 2023
Discovery & Translation
J&J’s fusion protein for Staph infection; plus cGAS for Alzheimer’s and more
BioCentury’s roundup of translational news
BioCentury | Jun 27, 2019
Product Development
Gene therapy’s next frontier lies beyond rare, monogenic diseases
How gene therapy is transitioning from single gene disorders to a modality of general use
BioCentury | Nov 17, 2017
Preclinical News
Memantine-based NMDA receptor antagonist could help treat autism
BioCentury | Jan 27, 2017
Emerging Company Profile
Cardiac conversion
Tenaya’s gene therapies aim to reverse heart failure by restoring heart muscle
BioCentury | Dec 17, 2015
Tools & Techniques
Heartfelt conversion
High efficiency, non-viral cell reprogramming
BioCentury | Dec 3, 2015
Distillery Therapeutics
Therapeutics: Heart and neural crest derivatives expressed 2 (HAND2); myocyte enhancer factor 2C (Mef2c); bone morphogenetic protein 4 (BMP4)
Items per page:
1 - 10 of 15